Abstract: The present invention relates to identification of a gene upregulated by interferon-a administration corresponding to the cDNA sequence set forth in SEQ. ID. NO. 1. Determination of expression products of this gene is proposed as having utility in predicting responsiveness to treatment with interferon-? and other interferons which act at the Type 1 interferon receptor. Therapeutic use of the protein encoded by the same geneis also envisaged.

Abstract: The present invention relates to identification of a gene upregulated by interferon-? administration corresponding to the cDNA sequence set forth in SEQ ID NO: 1. Determination of expression products of this gene is proposed as having utility in predicting responsiveness to treatment with interferon-a and other interferons which act at the Type 1 interferon receptor. Therapeutic use of the protein encoded by the same gene is also envisaged.

Abstract: The present disclosure relates to identification of previously known genes as being genes upregulated by interferon-? administration, in particular the human genes corresponding to the cDNA sequence in GenBank designated g4758303, g5453897, g4505186, g2366751, g33917, g4504962, g3978516, g5924396, g4505656, g1504007, g3702446, g4001802, g292289, g4557226, g4507646 and g4507170. Determination of expression products of these genes is proposed as having utility in predicting responsiveness to treatment with interferon-? and other interferons which act at the Type 1 interferon receptor.

Abstract: The present invention relates to identification of a gene upregulated by interferon-? administration corresponding to the cDNA sequence set forth in SEQ. ID. No. 1. Determination of expression products of this gene is proposed as having utility in predicting responsiveness to treatment with interferon-? and other interferons which act at the Type 1 interferon receptor. Therapeutic use of the protein encoded by the same gene is also envisaged.

Abstract: The present invention relates to identification of a gene upregulated by interferon-? administration corresponding to the cDNA sequence set forth in SEQ. ID. NO. 1. Determination of expression products of this gene is proposed as having utility in predicting responsiveness to treatment with interferon-? and other interferons which act at the Type 1 interferon receptor. Therapeutic use of the protein encoded by the same gene is also envisaged.

Abstract: The present disclosure relates to identification of genes upregulated by interferon-? administration, in particular the human genes corresponding to the cDNA sequences in GenBank designated g4586459, g2342476, g3327161 and g4529886. Determination of expression products of these genes is proposed as having utility in predicting responsiveness to treatment with interferon-? and other interferons which act at the Type 1 interferon receptor. Therapeutic use of the proteins encoded by the same genes is also envisaged.

Abstract: The present invention relates to identification of a gene upregulated by interferon-administration corresponding to the cDNA sequence set forth in SEQ. ID. No. 1. Determination of expression products of this gene is proposed as having utility in predicting responsiveness to treatment with interferon- and other interferons which act at the Type 1 interferon receptor. Therapeutic use of the protein encoded by the same gene is also envisaged.

Abstract: The present invention relates to identification of a gene upregulated by interferon-? administration corresponding to the cDNA sequence set forth in SEQ. ID. No. 1. Determination of expression products of this gene is proposed as having utility in predicting responsiveness to treatment with interferon-? and other interferons which act at the Type 1 interferon receptor. Therapeutic use of the protein encoded by the same gene is also envisaged.

Abstract: The present invention relates to identification of a gene upregulated by interferon-? administration corresponding to the cDNA sequences set forth in SEQ. ID. No. 1 or in SEQ. ID. No. 3. Determination of expression products of this gene is proposed as having utility in predicting responsiveness to treatment with interferon-? and other interferons which act at the Type 1 interferon receptor. Therapeutic use of the protein encoded by the same gene is also envisaged.

Abstract: The present invention relates to identification of a gene upregulated by interferon-&agr; administration corresponding to the cDNA sequence set forth in SEQ. ID. No. 1 and SEQ. ID. No. 3. Determination of expression products of this gene is proposed ahaigutility in predicting responsiveness to treatment with interferon-at and othe interferons which act at the Type 1 interferon receptor. Therapeutic use of the protein encoded by the same gene is also envisaged.

Abstract: The present invention relates to identification of a gene upregulated by interferon-administration corresponding to the cDNA sequence set forth in SEQ ID NO: 1. Determination of expression products of this gene is proposed as having utility in predicting responsiveness to treatment with interferon-&agr; and other interferons which act at the Type 1 interferon receptor. Therapeutic use of the protein encoded by the same gene is also envisaged.

Abstract: The present invention relates to identification of a gene upregulated by interferon-&agr; administration corresponding to the cDNA sequence set forth in SEQ.ID. No. 1. Determination of expression products of this gene is proposed as having utility in predicting responsiveness to treatment with interferon-&agr; and other interferons which act at the Type 1 interferon receptor. Therapeutic use of the protein encoded by the same gene is also envisaged.

Abstract: The present invention relates to identification of a gene upregulated by interferon-&agr; administration corresponding to the cDNA sequences set forth in SEQ. ID. No. 1 or in SEQ. ID. No. 3. Determination of expression products of this gene is proposed as having utility in predicting responsiveness to treatment with interferon-&agr; and other interferons which act at the Type 1 interferon receptor. Therapeutic use of the protein encoded by the same gene is also envisaged.

Abstract: The present disclosure relates to identification of genes upregulated by interferon-&agr; administration, in particular the human genes corresponding to the cDNA sequences in GenBank designated g4586459, g2342476, g3327161 and g4529886. Determination of expression products of these genes is proposed as having utility in predicting responsiveness to treatment with interferon-&agr; and other interferons which act at the Type 1 interferon receptor. Therapeutic use of the proteins encoded by the same genes is also envisaged.

Abstract: The present invention relates to identification of a gene upregulated by interferon-&agr; administration corresponding to he cDNA sequence set forth in SEQ. ID. No. 1. Determination of expression products of this gene is proposed as having utility in predicting responsiveness to treatment with interferon-&agr; and other interferons which act at the Type 1 interferon receptor. Therapeutic use of the protein encoded by the same gene is also envisaged.

Abstract: The present disclosure relates to identification of previously known genes as being genes upregulated by interferon-&agr; administration, in particular the human genes corresponding to the cDNA sequence in GenBank designated g4758303, g5453897, g4505186, g2366751, g33917, g4504962, g3978516, g5924396, g4505656, g1504007, g3702446, g4001802, g292289, g4557226, g4507646 and g4507170. Determination of expression products of these genes is proposed as having utility in predicting responsiveness to treatment with interferon-&agr; and other interferons which act at the Type 1 interferon receptor.